Literature DB >> 26101090

Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.

Zheng Ruan, Natarajan Kannan.   

Abstract

The epidermal growth factor receptor (EGFR) kinase is activated by a variety of mutations in human cancers. R776H is one such recurrent mutation (R752H in another numbering system) in the αC-β4 loop of the tyrosine kinase domain that activates EGFR in the absence of the activating EGF ligand. However, the mechanistic details of how R776H contributes to kinase activation are not well understood. Here using cell-based cotransfection assays, we show that the R776H mutation activates EGFR in a dimerization-dependent manner by preferentially adopting the acceptor position in the asymmetric dimer. The acceptor function, but not the donor function, is enhanced for the R776H mutant, supporting the "superacceptor" hypothesis proposed for oncogenic mutations in EGFR. We also find that phosphorylation of monomeric EGFR is increased by R776H mutation, providing insights into EGFR lateral phosphorylation and oligomerization. On the basis of molecular modeling and molecular dynamics simulation, we propose a model in which loss of key autoinhibitory αC-helix capping interaction and alteration of coconserved cis regulatory interactions between the kinase domain and the flanking regulatory segments contribute to mutational activation. Since the R776 equivalent position is mutated in ErbB2 and ErbB4, our studies have implications for understanding kinase mutational activation in other ErbB family members as well.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26101090      PMCID: PMC5937138          DOI: 10.1021/acs.biochem.5b00444

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  39 in total

1.  Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.

Authors:  Andrew J Shih; Shannon E Telesco; Sung-Hee Choi; Mark A Lemmon; Ravi Radhakrishnan
Journal:  Biochem J       Date:  2011-06-01       Impact factor: 3.857

Review 2.  EGF-ERBB signalling: towards the systems level.

Authors:  Ami Citri; Yosef Yarden
Journal:  Nat Rev Mol Cell Biol       Date:  2006-07       Impact factor: 94.444

3.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.

Authors:  Sander Pronk; Szilárd Páll; Roland Schulz; Per Larsson; Pär Bjelkmar; Rossen Apostolov; Michael R Shirts; Jeremy C Smith; Peter M Kasson; David van der Spoel; Berk Hess; Erik Lindahl
Journal:  Bioinformatics       Date:  2013-02-13       Impact factor: 6.937

4.  Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.

Authors:  Monica Red Brewer; Cai-Hong Yun; Darson Lai; Mark A Lemmon; Michael J Eck; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-09       Impact factor: 11.205

5.  Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.

Authors:  Hiroyuki Yasuda; Eunyoung Park; Cai-Hong Yun; Natasha J Sng; Antonio R Lucena-Araujo; Wee-Lee Yeo; Mark S Huberman; David W Cohen; Sohei Nakayama; Kota Ishioka; Norihiro Yamaguchi; Megan Hanna; Geoffrey R Oxnard; Christopher S Lathan; Teresa Moran; Lecia V Sequist; Jamie E Chaft; Gregory J Riely; Maria E Arcila; Ross A Soo; Matthew Meyerson; Michael J Eck; Susumu S Kobayashi; Daniel B Costa
Journal:  Sci Transl Med       Date:  2013-12-18       Impact factor: 17.956

Review 6.  The ErbB/HER family of protein-tyrosine kinases and cancer.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2013-11-20       Impact factor: 7.658

7.  Improved side-chain torsion potentials for the Amber ff99SB protein force field.

Authors:  Kresten Lindorff-Larsen; Stefano Piana; Kim Palmo; Paul Maragakis; John L Klepeis; Ron O Dror; David E Shaw
Journal:  Proteins       Date:  2010-06

8.  Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions.

Authors:  Kevin A James; Gennady M Verkhivker
Journal:  PLoS One       Date:  2014-11-26       Impact factor: 3.240

9.  Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

Authors:  Satoshi Watanabe; Yuji Minegishi; Hirohisa Yoshizawa; Makoto Maemondo; Akira Inoue; Shunichi Sugawara; Hiroshi Isobe; Masao Harada; Yoshiki Ishii; Akihiko Gemma; Koichi Hagiwara; Kunihiko Kobayashi
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

10.  Architecture and membrane interactions of the EGF receptor.

Authors:  Anton Arkhipov; Yibing Shan; Rahul Das; Nicholas F Endres; Michael P Eastwood; David E Wemmer; John Kuriyan; David E Shaw
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

View more
  12 in total

Review 1.  Dynamics-Driven Allostery in Protein Kinases.

Authors:  Alexandr P Kornev; Susan S Taylor
Journal:  Trends Biochem Sci       Date:  2015-10-21       Impact factor: 13.807

2.  Cancer-associated arginine-to-histidine mutations confer a gain in pH sensing to mutant proteins.

Authors:  Katharine A White; Diego Garrido Ruiz; Zachary A Szpiech; Nicolas B Strauli; Ryan D Hernandez; Matthew P Jacobson; Diane L Barber
Journal:  Sci Signal       Date:  2017-09-05       Impact factor: 8.192

Review 3.  Electrostatic Interactions in Protein Structure, Folding, Binding, and Condensation.

Authors:  Huan-Xiang Zhou; Xiaodong Pang
Journal:  Chem Rev       Date:  2018-01-10       Impact factor: 60.622

4.  Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.

Authors:  Zheng Ruan; Samiksha Katiyar; Natarajan Kannan
Journal:  Biochemistry       Date:  2016-12-22       Impact factor: 3.162

5.  Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.

Authors:  Thereasa A Rich; Karen L Reckamp; Young Kwang Chae; Robert C Doebele; Wade T Iams; Michael Oh; Victoria M Raymond; Richard B Lanman; Jonathan W Riess; Thomas E Stinchcombe; Vivek Subbiah; David R Trevarthen; Stephen Fairclough; Jennifer Yen; Oliver Gautschi
Journal:  Clin Cancer Res       Date:  2019-07-12       Impact factor: 12.531

6.  Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules.

Authors:  Zhenzhen Wu; Yanli Wang; Linling Jin; Juan Wei; Li Han; Junyan Su; Shuliang Cao; Siyao Liu; Xiaohong Duan; Xin Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-26       Impact factor: 4.322

7.  Altered conformational landscape and dimerization dependency underpins the activation of EGFR by αC-β4 loop insertion mutations.

Authors:  Zheng Ruan; Natarajan Kannan
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-13       Impact factor: 11.205

8.  Molecular basis for multimerization in the activation of the epidermal growth factor receptor.

Authors:  Yongjian Huang; Shashank Bharill; Deepti Karandur; Sean M Peterson; Morgan Marita; Xiaojun Shi; Megan J Kaliszewski; Adam W Smith; Ehud Y Isacoff; John Kuriyan
Journal:  Elife       Date:  2016-03-28       Impact factor: 8.140

Review 9.  Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model".

Authors:  Endang R Purba; Ei-Ichiro Saita; Ichiro N Maruyama
Journal:  Cells       Date:  2017-06-02       Impact factor: 6.600

10.  Rational design of non-resistant targeted cancer therapies.

Authors:  Francisco Martínez-Jiménez; John P Overington; Bissan Al-Lazikani; Marc A Marti-Renom
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.